Literature DB >> 4701549

Sphingolipid composition of human platelets.

R V Tao, C C Sweeley, G A Jamieson.   

Abstract

Total lipid extracts from washed trypsinized human platelets were fractionated into neutral lipids, glycosphingolipids, and phospholipids by silicic acid chromatography. The concentrations and chemical structures of the neutral and acidic glycosphingolipids were then studied in detail. On the basis of sugar molar ratios, studies of permethylation products, and the action of stereospecific glycosidases on the lipids, identifications were made of four neutral glycosphingolipids. Lactosylceramide was the most abundant type and accounted for 64% of the total neutral glycolipid mixture. The major fatty acids of the lactosylceramide were 20:0, 22:0, 24:0, and 24:1; the major long-chain base was 4-sphingenine. The platelets were surprisingly rich in a ceramide fraction, which represented 1.3% of the total platelet lipids. It had a different fatty acid composition than the neutral glycosphingolipid and ganglioside fractions. Hematoside was also isolated from the total lipid fraction of platelets; the neuraminic acid component was N-acetylneuraminic acid. Treatment of platelets with trypsin, chymotrypsin, or thrombin increased the yield of hematoside as compared with a control, while the level of ceramides was not changed. It was concluded that the platelets are similar to leukocytes, liver, and spleen in that lactosylceramide and hematoside are the principal neutral and acidic glycosphingolipids. The presence of a relatively high proportion of ceramide in platelets may be a unique characteristic of this cellular fraction of blood.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4701549

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  10 in total

1.  The effect of neuraminidase on the 5-hydroxytryptamine uptake of human platelets.

Authors:  W Gielen; B Viehöfer
Journal:  Experientia       Date:  1974-10-15

2.  Glycosphingolipids of human thyroid.

Authors:  J N Karli; G M Levis
Journal:  Lipids       Date:  1974-10       Impact factor: 1.880

3.  Palmitic acid-labeled lipids selectively incorporated into platelet cytoskeleton during aggregation.

Authors:  M A Packham; M A Guccione; N L Bryant; A Livne
Journal:  Lipids       Date:  1990-07       Impact factor: 1.880

4.  Neutrophil Extracellular Traps Induced by Shiga Toxin and Lipopolysaccharide-Treated Platelets Exacerbate Endothelial Cell Damage.

Authors:  Verónica Inés Landoni; Jose R Pittaluga; Agostina Carestia; Luis Alejandro Castillo; Marcelo de Campos Nebel; Daiana Martire-Greco; Federico Birnberg-Weiss; Mirta Schattner; Pablo Schierloh; Gabriela C Fernández
Journal:  Front Cell Infect Microbiol       Date:  2022-06-23       Impact factor: 6.073

5.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Lipid composition of sputum from patients with asthma and patients with cystic fibrosis.

Authors:  S Sahu; W S Lynn
Journal:  Inflammation       Date:  1978-03       Impact factor: 4.092

7.  Isolation and partial characterization of the neutral glycosphingolipids and gangliosides of the human heart.

Authors:  G M Levis; J N Karli; S D Moulopoulos
Journal:  Lipids       Date:  1979-01       Impact factor: 1.880

Review 8.  Reflections on my career in analytical chemistry and biochemistry.

Authors:  Charles C Sweeley
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 9.  Protection against Shiga Toxins.

Authors:  Simona Kavaliauskiene; Anne Berit Dyve Lingelem; Tore Skotland; Kirsten Sandvig
Journal:  Toxins (Basel)       Date:  2017-02-03       Impact factor: 4.546

Review 10.  Function of Platelet Glycosphingolipid Microdomains/Lipid Rafts.

Authors:  Keisuke Komatsuya; Kei Kaneko; Kohji Kasahara
Journal:  Int J Mol Sci       Date:  2020-08-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.